Research team describes novel tumor treatment

In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos in Scientific Reports has been published.

Nov 24, 2015
popularity90 comments 0

Flipping the switch to better see cancer cells at depths

Using a high-tech imaging method, a team of biomedical engineers at the School of Engineering & Applied Science at Washington University in St. Louis was able to see early-developing cancer cells deeper in tissue than ever ...

Nov 09, 2015
popularity16 comments 0

Gene therapy doubles survival in recurrent glioblastoma

An experimental gene therapy essentially doubled the overall survival of patients with recurrent glioblastoma compared to the current standard of care, a researcher said Oct. 1 at the Cancer Therapy & Research Center (CTRC) ...

Oct 01, 2015
popularity60 comments 0

Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system‎, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.

Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.

With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Researchers grow retinal nerve cells in the lab

Johns Hopkins researchers have developed a method to efficiently turn human stem cells into retinal ganglion cells, the type of nerve cells located within the retina that transmit visual signals from the eye to the brain. ...

Researchers find sleep gene linked to heart failure

Researchers at the Stanford University School of Medicine have identified a gene that, when working properly, appears to reduce the risk of heart failure and improve treatment outcomes, highlighting a possible target for ...